A new article introducing our nanophotonic device has been recently published in the BioOptics World section of Laser Focus World, a monthly trade magazine for optics industry professionals.A nice and comprehensible description of how our device works and its potential for diagnostics at the point of need.
Here you can find the Laser Focus Word article
The Unit of Biodetection belonging to the U4- NANBIOSIS has been recently upgraded with new optics and microfluidic components to improve its performance and increase its competitiveness with other similar equipment in the market.
The Unit of Biodetection, a Surface Plasmon Resonance (SPR) biosensor, available at the Unit is a highly sensitive device that allows the monitoring of biomolecular interactions in a real time label-free configuration.The optical device is based on the detection of the refractive index changes occurring in the sensing surface (i.e. metallic surface), which in turn can be related to mass changes as those occurring as a result of binding/desorption processes. With this actuation, some components have been updated (i.e. flow injection pimps, light sources, and spectrophotometer for signal output, among others) in order to increase the performance of the current design.
The ERDF funding was also used to update the UV/O3 Cleaner of the Biodeposition Unit belonging to the same NANBIOSIS Unit 4
At the ICN2, together with Phantoms Foundation, we are organizing the first online conference about COVID19 pandemics. The Biosensors for Pandemics Conference will be streamed worldwide on May 6th, joining top international researchers to discuss how new nanotech diagnostic systems can help in health emergency situations.
Prof. Laura M. Lechuga will give a Keynote presentation about the CoNVat project and how our advanced nanobiosensing platforms are being developed for point-of-care diagnostics and surveillance of coronavirus.
Visit the Conference Website and join us:
The current issue of Optics & Photonics News, the prestigious outreach journal of The Optical Society (OSA), highlights in the cover our recent publication Nanophotonic Biosensors: Driving Personalized Medicine.
In this feature, we provide a clear and understandable overview of the latest advances in optical biosensing platforms and their applications in healthcare. Photonic biosensors are a unique solution to accomplish more informative, timely and precise diagnosis of human diseases, and recently, they are also emerging as alternative tools to help in the development and general widespread of personalized therapies.
Have a look!
SensMOF is the new BIST IGNITE project that will be led by Dr. Leyre Gómez, postdoc in NanoB2A and NanoUP (Prof. Maspoch) groups at ICN2, together with ICREA Professor José Ramón Galán-Mascarós, from ICIQ.
The SensMOF project aims to develop new nanophotonic sensors for quantitative analysis of bioactive enantiomeric molecules, a current and major challenge for the pharmaceutical industry. We will work on a solution based on the so-called homochiral metal-organic frameworks, compounds composed by metal ions and organic ligands able to identify and separate enantiomers. This BIST collaboration will combine the expertise of different teams to create a scalable prototype that addresses the current industrial challenges of scalability and enantiomer separation process cost.
Our CoNVat project for new coronavirus diagnostics has been granted! The NanoB2A group will lead and coordinate a European research project to provide a point-of-care biosensor for the rapid detection of coronavirus. CoNVat is one of the 17 projects selected by the European Commission to be funded as urgent response to control and manage the COVID-19 outbreak.
Besides NanoB2A, CoNVat will engage top researchers in the fields of virology, clinical diagnostics, and epidemiology from Spain, France, and Italy. The group of Prof. Jordi Serra Cobo from the University of Barcelona provides an extensive experience in the study and epidemiology of coronavirus in reservoir animals and vectors. In France, the laboratory of Prof. Remi Charrel in the Aix-Marseille University is leader in virology and molecular biology, pioneering the development and production of biological material for the validation of new diagnostic systems. Finally, CoNVat also counts on the Italian National Institute of Infectious Diseases (INMI), the reference institute for the analysis and diagnosis of COVID-19. Researchers from Prof. Antonino di Caro's laboratory were among the first to isolate and sequence the human SARS-CoV-2 coronavirus.
With a duration of two years, the project aims to develop an advanced diagnostics system for real-time detection and identification of SARS-CoV-2 and other coronaviruses in both humans and reservoir species. The POC biosensor will be based on our proprietary nanophotonic technology (the BiMW interferometers) that enables ultrasensitive analysis of body fluids in few minutes and label-free fashion. The CoNVat system will be optimized and validated for a rapid population screening and identification of the new coronavirus among other clinically relevant viruses, like influenza. But further, the project will extend beyond the current pandemic and human diagnosis. The CoNVat biosensor will also be used for the analysis of different types of coronaviruses present in reservoir animals, such as bats, in order to observe and monitor possible evolutions of these viruses and prevent future outbreaks in humans.
On November 7, Jim M. Oschmann, President of the International Society for Optics and Photonics (SPIE), has come to the ICN2 to meet some of our institute’s scientists and visit our facilities. This was one stop of a longer tour of various Spanish laboratories organized for him by SPIE fellow and member of the Board of Directors Marta de la Fuente.
We have very much appreciated the visit and we enjoyed discussing about the present and future of science, especially in the field of photonics.